| Literature DB >> 31666833 |
Juliia Belikova1, Victor Lizogub1, Andrii Kuzminets2, Iryna Lavrenchuk2.
Abstract
The purpose of this study is to scrutiny the Dynamics of heart rate variability (HRV) in patients with PICS with 2nd type DM against the background of Taurine (TN) and meldonium (ME). The results of the investigations prove the decrease of the oxidative stress, which is basis of DACN, under the influence of sulfur-containing amino acid taurine (TN), and meldonium (ME) - a competitive inhibitor of gamma-butyrobetaine hydroxylase. Biochemical mechanisms of synergistic action of ME and TN are also described. The results of the studies of 98 patients with PICS and concomitant 2nd type diabetes mellitus were analyzed. They were distributed by simple randomization method into two groups, comparable according to age and sex: the main group (MG) (n = 68): and group of comparison (GoC) (n = 30). HRV was evaluated twice daily at the Cardiosense HMEGG system: at baseline and after 12 weeks of treatment. For the assessment of HRV the frequency and spectral parameters were used. While evaluating the different methods of treatment, their influence on the range of spectral and time indices of HRV was determined (p = 0.001 by the criterion of Kruskall-Wallis). It was learned that the combined application of ME and TN gives a statistically significant (p <0.01) increase of SDNN, HF at night, pNN - on 50% by day (p <0.01, p <0.001 and p <0.01 respectively), and statistically significant decrease in LF at night, compared to GHG. ©Carol Davila University Press.Entities:
Keywords: 2nd type diabetes meldonium; meldonium; postinfarction cardiosclerosis; taurine; variability of heart rate
Mesh:
Substances:
Year: 2019 PMID: 31666833 PMCID: PMC6814880 DOI: 10.25122/jml-2019-0052
Source DB: PubMed Journal: J Med Life ISSN: 1844-122X
The general characteristics of examined patients (Me (IQR))
| Index | Examined patients, n= 98 |
|---|---|
| Age | 64 (60-69) |
| Sex: male/female, n ,% | 50 (51.0%)/48(48.97%) |
| Age of DM, years | 7.69 (7.45-8.12) |
| Age of, years | 6.09 (5.35-8.02) |
| Body Mass Index, kg/ᴍ2 | 31.72 (27.8-39.11) |
| Accompanied cardiac unsufficiency (CН I), n, % | 98 (100.0 %) |
| Accompanied arterial hypertension, n (%) | 98 (100.0 %) |
| Homa index | 6.02 (5.11-6.16) |
| Official SBP, ᴍillimeters of mercury | 144.2 (126.7-154.5) |
| Official DBP, ᴍillimeters of mercury | 87.45 (86.7-88.37) |
| С-reactive protein, ᴍg/L | 3.74 (3.12-5.11) |
| Glycosylated hemoglobin, % | 7.92 (6.16-8.3) |
Time rates of HRV in patients with PICS and 2nd type DM against the background of taking taurine and meldonium dihydrate (Me (IQR))
| Index | Period of day | Main group patients (n=98) | Group of Comparison n=30 | Control group n=30 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1st Subgroup n=22 | 2nd Subgroup n= 23 | 3rd Subgroup n= 23 | ||||||||
| 1 | 2 | 1 | 2 | 1 | 2 | 1 | 2 | |||
| mRR | Day | 860.61 (845.3-871.22) | 887.4(865.2-891.1) | 854.3 (842.1-861) | 873.22 (868.1-881.3) | 864.3(859-867) | 910.21 (907.13-914) | 843.2 (831.1-856) | 846.2 (841.1-852.1) | 899.3 (871.1-901.1) |
| Night | 951.1 (931.1-972.2) # | 961.1 (915.1-971.1) | 873.2 (861-881.1) # | 961.4 (951.1-971.2) | 957.2 (951.1-959) # | 997.2(992-998) | 953,1 (952.6-961) # | 954.3 (952.2-961) | 915.43 (913.4-931) | |
| SDNN | Day | 36.41 (35.21-37.2) # | 37.45 (32.65-39.1) | 36.33 (35.77-37.9) # | 38.11 (37.87-41.1) | 35.12 934.67-37.2) # | 41.11 (40.54-42.3) ^ | 35.34 934.32-36.78) # | 35 .58 (32.12-38.91) | 47.14 944.31-51.2) |
| Night | 41.13 (40.36-42.16) # | 42.2 (41.65-43.1) | 40.2 940.1-41) # | 41.3 940.34-42) # | 42.4 (41.5-45) # | 45.03 (44.2-44) * ^ | 42.1 (41.1-43) # | 43.2 (42.4-44) | 59.11 (56.8-61) | |
| RMSSD | Day | 19.7 (18.3-21) | 21.3 920.1-22) | 24.01 923-25.2) | 25.1 (24.4-27) | 20 .3 919.9-24) | 23.1 (22.1-25) * | 20.2 (18.9-22) | 21.2 (19.9-21) | 24.1 (23.2-25) |
| Night | 24.1 (23.1-26) | 26.2 (23-27.2) | 31.1 (28.2-34) | 34.2 (33.1-35) | 26.2 (25.3-27) | 33.1 (31.2-34) * | 28.2 923-29.2) | 35.4 (34.1-37) | 31.2 (30.3-34) | |
| pNN 50, % | Day | 2.5 (1.97-2.7) | 2.7 (2.34-2.8) | 2.3(2.21-2.6) | 2.4(2.23-2.7) | 2.8 92.54-2.9) | 4.1 (3.97-4.13) * ^ | 2.9 (2.87-3.12) | 3.3(3.1-3.7) ^ | 6.3 (6.1-6.21) |
| Night | 4.5 (4.41-4.7) | 4.7(4.6-4.81) | 6.1 95.93-6.1) | 6.2 (6.13-6.23) | 4.9 (4.7-5.1) | 6.12 (6.1-6.17)^ | 5.1(4.97-5.4) | 5.1(5.0-5.15) | 8.1 (8.1-8.65) | |
| Circadian index, | ----- | 1.2 (1.17-1.3) # | 1.25(1.24-1.27) | 1.9 (1.8-2.1) # | 1.24 (1.17-1.26) | 1.2 (1.14-1.25) # | 1.27 (1.24-1.3) | 1.2 (1.15-1.28) # | 1.22 (1.17-1.29) | 1.34 (1.31-1.4) |
Notes: before 1st-treatment, after 12 weeks of treatment, # - p <0,05 ## - p <0,001 compared to GOC * - p <0,01 ** - p <0,001 - compared with the indicators up to 12 weeks of treatment, ^ - p <0,01 ^^ - p <0,001 - compared with GH after 12 weeks of treatment
Spectral indices of HRV in patients with PICS and 2nd type DM against the background of receiving taurine and meldonium dihydrate (Me (IQR))
| Index | Main group, n= 68 | Group of Comparison n= 30 | COG n= 30 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1st Subgroup n=22 | 2nd Subgroup n=23 | 3rd Subgroup n=23 | |||||||||||
| Day | Night | Day | Night | Day | Night | Day | Night | Day | Night | ||||
| TP, mc2 | 1 | 1523.54 (1487.6-1525) ## | 1870.81 (1756.1-1223) ## | 1531.1 (1518-1541) ## | 1910.1 (1907-1913) ## | 1528.2 (1514-1531 ##) | 1925.1 (1914-1917.1 ##) | 1532.2 (1527-1534) ## | 1911.12 (1905-1923) ## | 3421.15 (3420-3423) | 3120.11 93101-3123.5) | ||
| 2 | 1630.13 (1625-1634) | 2010.1 92007-2012.1) | 1634.3 (1631-1643) | 1997.2 (1993-1999) | 1970.2 (1965-1974) | 2350.2 (2346-2356) | 1643.4 (1634-1651) | 1987.1 (1983-1991) | |||||
| VLF, mc2 | 1 | 705 ## | 951.52 (881-1015.67) | 707.5 (705.3-709.4) ## | 934.3 (928.1-941.2) | 710.5 (707.9-711.2) ## | 921.2 (918.1-923.2) | 707.3 (705.1-709.7) ## | 924.3 (921.4-926.7) | 1110.3 (1101-115.5) | 1311.2 (1223-1345.2) | ||
| 2 | 711.2 (707-714) | 972.2 (968-974) | 717.79 (715-719) | 961.2 996=57-964) | 753.2 (751-755) | 1017.2 (1015-1019) | 709.2 9707.3-711) | 943.2 9941-955) | |||||
| ULF, mc2 | 1 | 552.68 (478-565.6) | 407.31 (398.61-415.8) | 557.2 (551-561) | 410.12 (404-412) | 553.1 (551-557) | 410.2 (407-412) | 543.2 (541-551) | 411.2 (407-414) | 984.13 (981-991) | 557.12 (551-559) | ||
| 2 | 572.2 (571-575) | 412.3 (411-414) | 565.1 (562-571) | 421.2 (419.1-424) | 640.2 (638-641) | 450.2 (447-454) | 545.1 (537-545) | 412.2 (411-415) | |||||
| HF, mc2 | 1 | 110.12 (98.61-115.63) | 201.43 ## (178.6-215.65) | 112.2 (1.1-113) | 205.3 (201-207) ## | 112.1 (11.3-113) | 203.1 (202-205) ## | 110.2 (108-111) | 207.1 (25-2111.3) ## ^^ | 365.43 (363-341.2) | 515.3 (513-517) | ||
| 2 | 134.2 (112-136) | 223.4 (221-225.1) | 143.1 (137.1-142) | 251 (243-254.7) | 190.7 (187-201) | 291.3 (296-302) ** | 143.6 (141-147) | 214.5 (212-216) | |||||
| LF, mc2 | 1 | 220.76 ## (198.61-235.6) | 421.49 ## (376.6-515.03) | 223.12 (221-225.2) ## | 421.2 (419-423.2) ## | 231.2 (230-234.2) ## | 430.3 (427-432.5) ## | 223.3 (221-225) ## | 427.2 (424-431)## | 650.12 (645-661.2) | 702.13 (701-705.5) | ||
| 2 | 241(237-251) | 441 (367-487) | 236 (224-254.1) | 441.3(427.6-451.2) | 291.3 (278.3-301.1) | 460.2 (457.1-462.3) | 236.4 (234.5-239.3) | 429.1(418.7-432.2) | |||||
| LF/HF | 1 | 2.6 (2.1-2.7) ## | 2.4 (2.1-2.8) ## | 2.7(2.2-2.9) ## | 2.5(2.1-2.9) ## | 2.8 (2-3.1)## | 2.5(1.9-3) ## | 2.9(1.5-3) ## | 2.4 (2-2.6) ## | 2.1 (1.9-2.5) | 1.72 (1.3-1.9) | ||
| 2 | 1.9 (1.8-2.1) | 2.2 (1.8-2.5) | 2.3 (1.9-2.1) | 2.3 (1.5-2.5) | 1.6(1.4-1.9) | 1.5 (1.3-1.7) | 2.6(2.1-2.8) | 2.3 (2.1-2.8) | |||||
Notes: before 1st-treatment, after 12 weeks of treatment, * - p <0.01, ** - p <0.001 - compared with the indices before treatment, ## - p <0.001 compared with GOC, ^ - p <0.01 ^^ - p <0,001 -compared with SG after 12 weeks of treatment.